{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:07Z","timestamp":1791223507631,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00296-011-2030-8","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T08:41:40Z","timestamp":1311583300000},"page":"2675-2679","source":"Crossref","is-referenced-by-count":28,"title":["Is it safe to use anti-TNF-\u03b1 agents for tuberculosis in children suffering with chronic rheumatic disease?"],"prefix":"10.1007","volume":"32","author":[{"given":"Omer","family":"Kilic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Kasapcopur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yildiz","family":"Camcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Cokugras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil","family":"Arisoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necla","family":"Akcakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"2030_CR1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.pcl.2005.01.007","volume":"52","author":"JE Weiss","year":"2005","unstructured":"Weiss JE, Ilowite NT (2005) Juvenile idiopathic arthritis. Pediatr Clin North Am 52:413\u2013442","journal-title":"Pediatr Clin North Am"},{"key":"2030_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/adc.2009.170860","volume":"94","author":"MW Beresford","year":"2009","unstructured":"Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis-2: the era of biologicals. Arch Dis Child Educ Pract Ed 94:151\u2013156","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2030_CR3","volume-title":"Global tuberculosis control: surveillance, planning, financing","author":"WHO Report","year":"2007","unstructured":"WHO Report (2007) Global tuberculosis control: surveillance, planning, financing. WHO, Geneva"},{"key":"2030_CR4","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/ndt\/gfl416","volume":"21","author":"U Sester","year":"2006","unstructured":"Sester U, Junker H, Hodapp T, Sch\u00fctz A, Thiele B, Meyerhans A et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transpl 21:3258\u20133268","journal-title":"Nephrol Dial Transpl"},{"key":"2030_CR5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7","volume":"45","author":"WP Arend","year":"2001","unstructured":"Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthr Rheum 45:101\u2013106","journal-title":"Arthr Rheum"},{"key":"2030_CR6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","volume":"84","author":"NF Crum","year":"2005","unstructured":"Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-\u03b1 antagonists. Medicine (Baltimore) 84:291\u2013302","journal-title":"Medicine (Baltimore)"},{"key":"2030_CR7","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ G\u00f3mez-Reino","year":"2003","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthr Rheum 48:2122\u20132127","journal-title":"Arthr Rheum"},{"key":"2030_CR8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261\u20131265","journal-title":"Clin Infect Dis"},{"key":"2030_CR9","first-page":"1153","volume":"168","author":"R Long","year":"2003","unstructured":"Long R, Gardam M (2003) Tumour necrosis factor-\u03b1 inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168:1153\u20131156","journal-title":"CMAJ"},{"key":"2030_CR10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","volume":"39","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder M, Wong J, Beenhouwer D (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39:1254\u20131255","journal-title":"Clin Infect Dis"},{"key":"2030_CR11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2005.10.004","volume":"72","author":"F Tubach","year":"2005","unstructured":"Tubach F, Salmon-C\u00e9ron D, Ravaud P, Mariette X (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF alpha therapy. Joint Bone Spine 72:456\u2013460","journal-title":"Joint Bone Spine"},{"key":"2030_CR12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","volume":"194","author":"OY Saliu","year":"2006","unstructured":"Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486\u2013492","journal-title":"J Infect Dis"},{"key":"2030_CR13","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V, Montero D, Pascual-G\u00f3mez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum 52:1766\u20131772","journal-title":"Arthr Rheum"},{"key":"2030_CR14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","volume":"30","author":"T Cagatay","year":"2010","unstructured":"Cagatay T, Ayd\u0131n M, Sunmez S, Cagatay P, Gulbaran Z, Gul A et al (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30:1459\u20131463","journal-title":"Rheumatol Int"},{"key":"2030_CR15","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","volume":"52","author":"KL Winthrop","year":"2005","unstructured":"Winthrop KL, Seigel JN, Jereb J, Taylor Z, Iademarco MF (2005) TB associated with therapy against tumor necrosis factor \u03b1. Arthr Rheum 52:2968\u20132974","journal-title":"Arthr Rheum"},{"key":"2030_CR16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10165-009-0259-9","volume":"20","author":"S Yokota","year":"2010","unstructured":"Yokota S, Mori M, Imagawa T, Murata T, Tomiita M, Itoh Y et al (2010) Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. Mod Rheumatol 20:107\u2013113","journal-title":"Mod Rheumatol"},{"key":"2030_CR17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62:791","journal-title":"Ann Rheum Dis"},{"key":"2030_CR18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobactcerium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800\u2013805","journal-title":"Thorax"},{"key":"2030_CR19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161:221\u2013247","journal-title":"Am J Respir Crit Care Med"},{"key":"2030_CR20","first-page":"620","volume":"137","author":"C Beglinger","year":"2007","unstructured":"Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM et al (2007) Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 137:620\u2013622","journal-title":"Swiss Med Wkly"},{"key":"2030_CR21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.imlet.2006.08.002","volume":"107","author":"M Vukmanovic-Stejic","year":"2006","unstructured":"Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93\u2013101","journal-title":"Immunol Lett"},{"key":"2030_CR22","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3899\/jrheum.090173","volume":"36","author":"E Kiray","year":"2009","unstructured":"Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N et al (2009) Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 36:2029\u20132032","journal-title":"J Rheumatol"},{"key":"2030_CR23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10067-009-1334-5","volume":"29","author":"NA Ayaz","year":"2010","unstructured":"Ayaz NA, Demirkaya E, Bilginer Y, Ozcelik U, Cobanoglu N, Kiper N et al (2010) Preventing tuberculosis in children receiving anti-TNF treatment. Clin Rheumatol 29:389\u2013392","journal-title":"Clin Rheumatol"},{"key":"2030_CR24","doi-asserted-by":"crossref","unstructured":"Cagatay T, Kilicaslan Z, Cagatay P, Mertsoylu M, Gulbaran Z, Yildiz R et al (2010) TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int Mar 27 (Epub ahead of print)","DOI":"10.1007\/s00296-010-1424-3"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2030-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-011-2030-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2030-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T04:57:07Z","timestamp":1560401827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-011-2030-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["2030"],"URL":"https:\/\/doi.org\/10.1007\/s00296-011-2030-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]}}}